[
  {
    "ts": null,
    "headline": "Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 4, Scotiabank raised its price target on Merck & Co., Inc. (NYSE:MRK) to $136 from $120 and maintained an Outperform rating. The firm said the higher target reflects multiple expansion, noting that Merck’s execution continues […]",
    "url": "https://finnhub.io/api/news?id=460e9c99c8ab0cd773fd35bc0b0836c537e277084a30fb875a231d33da7af935",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770320292,
      "headline": "Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress",
      "id": 138367523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 4, Scotiabank raised its price target on Merck & Co., Inc. (NYSE:MRK) to $136 from $120 and maintained an Outperform rating. The firm said the higher target reflects multiple expansion, noting that Merck’s execution continues […]",
      "url": "https://finnhub.io/api/news?id=460e9c99c8ab0cd773fd35bc0b0836c537e277084a30fb875a231d33da7af935"
    }
  },
  {
    "ts": null,
    "headline": "Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut",
    "summary": "Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 ​million after its shares opened 5.",
    "url": "https://finnhub.io/api/news?id=4b7633ca0eb5a5764cfa23fc0e9d1522213e398e868420e9949785151c498ed6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770315710,
      "headline": "Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut",
      "id": 138367524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 ​million after its shares opened 5.",
      "url": "https://finnhub.io/api/news?id=4b7633ca0eb5a5764cfa23fc0e9d1522213e398e868420e9949785151c498ed6"
    }
  },
  {
    "ts": null,
    "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
    "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines.",
    "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305054,
      "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
      "id": 138376237,
      "image": "https://image.cnbcfm.com/api/v1/image/108262460-1770383887859-gettyimages-2259525568-TRUMPRX_LAUNCH.jpeg?v=1770384067&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines. ",
      "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
    "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
    "url": "https://finnhub.io/api/news?id=64329d8ff9d20284c5cc2c4b877e09f0b7c4d9b8b97abb784b992b951a8d48ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300900,
      "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
      "id": 138366124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
      "url": "https://finnhub.io/api/news?id=64329d8ff9d20284c5cc2c4b877e09f0b7c4d9b8b97abb784b992b951a8d48ee"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?",
    "summary": "AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.",
    "url": "https://finnhub.io/api/news?id=030098ecabf82c44af9fa2fdffc694a9f6d1e336179ea0724606e651642b5acf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770298260,
      "headline": "AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?",
      "id": 138364487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.",
      "url": "https://finnhub.io/api/news?id=030098ecabf82c44af9fa2fdffc694a9f6d1e336179ea0724606e651642b5acf"
    }
  },
  {
    "ts": null,
    "headline": "Final Trades: Merck, Zoom, Palantir and Kinsale Capital Group",
    "summary": "The Investment Committee give you their top stocks to watch for the second half.",
    "url": "https://finnhub.io/api/news?id=5347c3e4e42777b26869864adeb3077e76b94f33b911ad2e6cabecbaf1bb2603",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296817,
      "headline": "Final Trades: Merck, Zoom, Palantir and Kinsale Capital Group",
      "id": 138376247,
      "image": "https://image.cnbcfm.com/api/v1/image/108262072-17703145131770314511-43866772444-1080pnbcnews.jpg?v=1770314513&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "The Investment Committee give you their top stocks to watch for the second half.",
      "url": "https://finnhub.io/api/news?id=5347c3e4e42777b26869864adeb3077e76b94f33b911ad2e6cabecbaf1bb2603"
    }
  },
  {
    "ts": null,
    "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
    "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
    "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296280,
      "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
      "id": 138364449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
      "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants",
    "summary": "Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants born during or entering their first RSV season.",
    "url": "https://finnhub.io/api/news?id=d06d245a365cf91af1fb4b37b766a069bce5da9a6c4bdb5305593e0f98d2e2df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770293100,
      "headline": "Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants",
      "id": 138363558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants born during or entering their first RSV season.",
      "url": "https://finnhub.io/api/news?id=d06d245a365cf91af1fb4b37b766a069bce5da9a6c4bdb5305593e0f98d2e2df"
    }
  },
  {
    "ts": null,
    "headline": "J.P. Morgan Healthcare Conference 2026 Report",
    "summary": "The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at the J. P. Morgan Healthcare Conference 2026.",
    "url": "https://finnhub.io/api/news?id=f3ae21a40e53769ff7475868bf1e62df54959830e830e03268495e94fad45f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770288270,
      "headline": "J.P. Morgan Healthcare Conference 2026 Report",
      "id": 138362692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at the J. P. Morgan Healthcare Conference 2026.",
      "url": "https://finnhub.io/api/news?id=f3ae21a40e53769ff7475868bf1e62df54959830e830e03268495e94fad45f67"
    }
  },
  {
    "ts": null,
    "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
    "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
    "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770282000,
      "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
      "id": 138362075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
      "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma CEOs set sights on massive growth in years to come",
    "summary": "The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.",
    "url": "https://finnhub.io/api/news?id=332f26e987f5d515a897b364ec918ce084a25c401a4509a3eb9a878473ef004b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770278400,
      "headline": "Big Pharma CEOs set sights on massive growth in years to come",
      "id": 138364455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.",
      "url": "https://finnhub.io/api/news?id=332f26e987f5d515a897b364ec918ce084a25c401a4509a3eb9a878473ef004b"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks with Promising Prospects and 1 We Brush Off",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 9.8%.",
    "url": "https://finnhub.io/api/news?id=9866b6215732e5e4e327cf7abfe46baa43f7c8587b63888c8ba8a1c6d4b4fbff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770266162,
      "headline": "2 Healthcare Stocks with Promising Prospects and 1 We Brush Off",
      "id": 138362693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 9.8%.",
      "url": "https://finnhub.io/api/news?id=9866b6215732e5e4e327cf7abfe46baa43f7c8587b63888c8ba8a1c6d4b4fbff"
    }
  }
]